COMP <GO>
MMED vs JNJ // NET PROFIT MARGIN
MiniMed Group Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MMED 2
— JNJ 11
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $18.28 (-5.04%) • MKT CAP: $5.42B
net-margins
-10.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.20% | 67.90% | -13.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 25.50% | -29.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 2.97% | -10.72 | JNJ | /fcf-yield <GO> |
| Operating Margin | -6.10% | 34.70% | -40.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -10.70% | 28.50% | -39.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 6.00% | +8.30 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.82 | 5.59 | -0.77 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | MMED | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 60.4 | -16.53 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 23.0x | +1.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $662.49B | -$657.08B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | JNJ REV | MMED GROSS % | JNJ GROSS % | MMED FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $94.19B | 54.2% | 67.9% | -$420.0M | $19.70B |
| FY 2024 | $2.71B | $88.82B | 56.3% | 69.1% | -$53.0M | $19.84B |
| FY 2023 | $2.47B | $85.16B | 44.0% | 44.0% | -$70.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
JNJ // BETA 1.08